Innate Pharma Operating Income

Innate Pharma (IPHA) currently reports a operating income of $-95M as of December 2025. That compares with $-42M in the prior-year period — down 128.3% year over year. Use the charts on this page to explore Innate Pharma's operating income history and peer comparisons.

Innate Pharma's operating income decreased from $-42M to $-95M — a 128.3% year-over-year decrease (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Innate Pharma reported $-95M in operating income as of December 2025. That compares with $-42M in the prior-year period — down 128.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-95M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Innate Pharma, and consider following IPHA for alerts when major investors trade the stock.

Innate Pharma is classified in the Healthcare sector. On operating income, it currently shows $-95M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IPHA with unrelated industries.